Dec 28, 2010 (M2 EQUITYBITES via COMTEX) --
28 December 2010 - Stockholm-listed pharma company Epicept Corp (STO: EPCT) said today its US partner Myrexis Inc (NASDAQ: MYRX |PowerRating) has initiated a phase IIb clinical trial with brain tumour treatment Azixa.
The controlled two-arm study will compare Azixa in addition to standard of care with standard of care alone as a front-line treatment for glioblastoma multiforme (GBM). The trial will enrol up to 120 newly-diagnosed GBM patients in the USA and India.
Azixa, which is currently being tested in other phase II studies, is a vascular disruption agent that was discovered by Epicept as part of its anti-cancer screening apoptosis platform (ASAP). In December 2003, the company granted exclusive, worldwide development and commercialisation rights to its EP90745 series of apoptosis inducer compounds, including Azixa, to Myrexis. If a product from the series is commercialised, Epicept is entitled to milestone payments, license fees and royalty on sales.
Comments on this story may be sent to info@m2.com
For full details on Myriad Pharmaceuticals Incorporated (MYRX) MYRX. Myriad Pharmaceuticals Incorporated (MYRX) has Short Term PowerRatings at TradingMarkets. Details on Myriad Pharmaceuticals Incorporated (MYRX) Short Term PowerRatings is available at This Link.
